Market Place
Sourcing Support
Phathom Submits Citizen Petition To FDA For Voquezna Listings
11 Dec 2024 //
GLOBENEWSWIRE
Lupin partners with Takeda to commercialise Vonoprazan
18 Sep 2024 //
EXPRESSPHARMA
Alkem inks licensing pact with Takeda to introduce Vonoprazan in India
03 Sep 2024 //
ECONOMICTIMES
Phathom Pharma Reports Q2 2024 Results And Provides Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Phathom`s VOQUEZNA® Added To CVS Caremark Commercial Formularies
30 Jul 2024 //
GLOBENEWSWIRE
Dr Reddy`s inks licensing pact with Takeda to sell gastrointestinal drug
20 Jul 2024 //
PRESS RELEASE
Dr. Reddy`s Signs Licensing Deal With Takeda For Vonoprazan
19 Jul 2024 //
PRESS RELEASE
FDA Approves Phathom`s VOQUEZNA For Non-Erosive GERD Heartburn Relief
18 Jul 2024 //
GLOBENEWSWIRE
Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India
16 Jul 2024 //
INDIANPHARMAPOST
Phathom To Present VOQUEZNA Data At DDW 2024 Annual Meeting
15 May 2024 //
GLOBENEWSWIRE
Phathom’s first campaign for acid blocker Voquezna is latest to use telehealth
26 Mar 2024 //
ENDPTS
Phathom Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
26 Mar 2024 //
PR NEWSWIRE
Phathom Pharmaceuticals Announces VOQUEZNA (vonoprazan) Tablets for Erosive GERD
13 Feb 2024 //
GLOBENEWSWIRE
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA
06 Dec 2023 //
GLOBENEWSWIRE
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA
28 Nov 2023 //
GLOBENEWSWIRE
US approves Phathom`s Voquezna for erosive GERD
02 Nov 2023 //
GLOBENEWSWIRE
Phathom Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA
30 Oct 2023 //
GLOBENEWSWIRE
Phathom to resubmit applications for Voquezna in coming months
04 Apr 2023 //
FIERCE PHARMA
Phathom Faces Another Delay with H. pylori, Esophagitis Drugs
11 Feb 2023 //
BIOSPACE
Phathom Pharma Shares Fall After Formal FDA Request For Vonoprazan Data
10 Feb 2023 //
FINANCE YAHOO
2022 drug approvals: Biopharma delivered 37 new drugs
03 Jan 2023 //
FIERCE PHARMA
Phathom Provides Update on New Drug Application Review of Vonoprazan
03 Jan 2023 //
GLOBENEWSWIRE
Evonik and Phathom partner to produce novel acid-blocker vonoprazan
24 Oct 2022 //
PRESS RELEASE
Phathom Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily
24 Oct 2022 //
GLOBENEWSWIRE
Phathom Pharma to Present Latest Data on Vonoprazan at ACG
18 Oct 2022 //
GLOBENEWSWIRE
Catalent Supports U.S. Launch of Phathom`s New Products
11 Jun 2022 //
WFMZ
Phathom Pharmaceuticals Presents Data on Novel PCAB Vonoprazan
24 May 2022 //
GLOBENEWSWIRE
Phathom Pharma wins FDA approval for antibacterial tablets
05 May 2022 //
SEEKING ALPHA
Phathom Pharma Submits Vonoprazan NDA to FDA for Erosive Esophagitis
14 Mar 2022 //
GLOBENEWSWIRE
Phathom Shows Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan
09 Feb 2022 //
GLOBENEWSWIRE
Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific
21 Oct 2021 //
GLOBENEWSWIRE
Phathom`s old Takeda drug bests Prevacid in PhIII GI trial
19 Oct 2021 //
ENDPTS
Phathom Submits Two NDAs for Vonoprazan-based Treatment for H. pylori Infection
08 Sep 2021 //
GLOBENEWSWIRE
Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial
23 Dec 2019 //
BUSINESS WIRE
INmune Bio,Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study
02 Dec 2019 //
GLOBENEWSWIRE
Phathom`s Announces Initiation of Pivotal Ph3 Clinical Trial for Vonoprazan
02 Dec 2019 //
BUSINESS WIRE
